Genzyme Genetics enhances diagnostic system:
This article was originally published in Clinica
Executive Summary
Cambridge, Massachusetts-based Genzyme Genetics, a unit of Genzyme General, has expanded its cancer testing services by "significantly stepping up" its flow cytometry programme performed in laboratories in Santa Fe, Mexico. Dr Bruce Davis, associate director for clinical research at Maine Medical Center, will direct staff interpreting test results and providing consultation services to physicians. The company has also compiled a database to assist in the interpretation of complex cases. Physicians will have secure internet access to test results as they become available. Flow cytometry diagnoses leukaemia, lymphoma, multiple myeloma among other cancers, monitors residual levels of disease present in post-treatment patients and is used as an evaluative tool of patients whose treatment is likely to fail.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.